AssayIndex
Tissue-repair and immunomodulatory peptides

VIP

vasoactive intestinal peptide · aviptadil · C147H238N44O42S · monoisotopic 3324.8146 Da. The index holds 12 assay reports on this compound across 2 batches from 2 suppliers.

12 reports2 batchesmedian 97.56 %index spec 97.5 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

VIP is the least stable compound the index tracks in solution: measurable degradation within hours at room temperature in unbuffered water. Reports must state the interval between reconstitution and injection, and the index excludes VIP records where that interval exceeded four hours from the purity aggregates while still publishing the record. Thin coverage, n under 40.

Molecular formula
C147H238N44O42S
Monoisotopic mass
3324.8146Da
Average mass
3326.83Da
Residues
28
Nominal retention (RG-2, 30 min)
12.98min
Retention window
0.35min
Counter-ion as usually shipped
acetate
Typical label claims
1 mg · 2 mg · 5 mg
Analytical difficulty (index scale)
1.15 — moderate
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

02030406060898119 VIP12.98 min · 97.56 % 12.32 same trace · ×20 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative VIP trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 97.56 % area at the nominal retention time of 12.98 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 12 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 97.56% n=12
Interquartile range 0.58pp n=12
Minimum 96.37% n=12
Maximum 99.28% n=12
Pass rate vs spec 58.3% n=12
Median recovery vs claim 92.9% n=10
Median water 5.13% n=12
Median |mass error| 3.2ppm n=10
02492.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=196.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=497.50–97.75 %: n=497.75–98.00 %: n=098.00–98.25 %: n=098.25–98.50 %: n=098.50–98.75 %: n=098.75–99.00 %: n=299.00–99.25 %: n=099.25–99.50 %: n=199.50–99.75 %: n=099.75–100.00 %: n=0median 97.56 Purity (% area) Reports
Figure 2. Purity distribution across all 12 VIP records. Dashed line is this compound's median (97.56 %); the solid vertical is the index acceptance specification for the tissue-repair and immunomodulatory peptides class (97.5 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

96.196.797.397.898.499.099.5BCHBCH: Q1 97.39, median 97.43, Q3 97.61, n=9outlier 96.37n=9TFCTFC: Q1 98.88, median 98.95, Q3 99.12, n=3n=3 Purity (% area)
Figure 3. VIP purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
Met17 sulfoxide (+16 Da)-0.66+15.995100%1.352.39
C-terminal free acid (+1 Da)+0.28+0.984100%0.500.67
des-His1 (−137 Da)-0.82-137.059100%0.260.40
deamidated (+1 Da)-0.30+0.984100%0.230.74

Degradation pathways

  • Met17 oxidation
  • C-terminal amide hydrolysis
  • rapid aqueous instability — hours, not days

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Aviptadil was studied for COVID-19-associated respiratory failure; results did not support approval.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q3997.4396.37–97.70
2024-Q40n<3—
2025-Q10n<3—
2025-Q2398.9598.82–99.28
2025-Q30n<3—
2025-Q40n<3—
2026-Q10n<3—
2026-Q20n<3—
2026-Q30n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent VIP records of 12.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-019550TFCTFC-2503-E9984Janoshik2025-Q298.824.2390.1Buyer-sourced0PASS
AX-2025-019551TFCTFC-2503-E9984PeptideMeter2025-Q298.954.0892.4Buyer-sourced1FAIL
AX-2025-019549TFCTFC-2503-E9984Medutest2025-Q299.283.9289.6Buyer-sourced1MARGINAL
AX-2024-005269BCHBCH-2405-R4888Janoshik2024-Q397.345.2799.6Buyer-sourced0FAIL
AX-2024-005266BCHBCH-2405-R4888Janoshik2024-Q397.434.81—Supplier-supplied0FAIL
AX-2024-005265BCHBCH-2405-R4888Medutest2024-Q397.625.82100.3Buyer-sourced0PASS
AX-2024-005264BCHBCH-2405-R4888Janoshik2024-Q397.415.9390.7Buyer-sourced0FAIL
AX-2024-005272BCHBCH-2405-R4888Nordanalyt2024-Q397.615.22—Buyer-sourced0PASS
AX-2024-005267BCHBCH-2405-R4888Janoshik2024-Q397.525.6890.8Buyer-sourced0PASS
AX-2024-005271BCHBCH-2405-R4888VendorInvestigate2024-Q396.375.0493.4Buyer-sourced0FAIL
AX-2024-005268BCHBCH-2405-R4888Kestrel2024-Q397.704.42106.9Buyer-sourced0PASS
AX-2024-005270BCHBCH-2405-R4888VendorInvestigate2024-Q397.395.4196.9Buyer-sourced0FAIL